Genfit S.A.

OTCPK:GNFT.Y Voorraadrapport

Marktkapitalisatie: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Toekomstige groei

Future criteriumcontroles 4/6

Genfit zal naar verwachting groeien in winst en omzet met respectievelijk 25.5% en 11% per jaar. De winst per aandeel zal naar verwachting groeien met 103.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -2.5% zijn.

Belangrijke informatie

25.5%

Groei van de winst

103.22%

Groei van de winst per aandeel

Biotechs winstgroei25.2%
Inkomstengroei11.0%
Toekomstig rendement op eigen vermogen-2.51%
Dekking van analisten

Good

Laatst bijgewerkt27 Feb 2026

Recente toekomstige groei-updates

Geen updates

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Winst- en omzetgroeiprognoses

OTCPK:GNFT.Y - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202867-29-15-153
12/31/20271078116
12/31/2026769226
12/31/202569-39-66
6/30/202545-39-7-3N/A
3/31/202558-1946N/A
12/31/20247121516N/A
9/30/20247612-14-13N/A
6/30/20248022-43-42N/A
3/31/202457-3-50-48N/A
12/31/202334-29-58-55N/A
9/30/202332-32-55-53N/A
6/30/202329-34-52-50N/A
3/31/202328-29-62-61N/A
12/31/202226-24-73-73N/A
9/30/2022601244N/A
6/30/202294488080N/A
3/31/202290589090N/A
12/31/2021856799100N/A
9/30/202146141011N/A
6/30/20216-39-79-79N/A
3/31/20217-70-88-88N/A
12/31/20209-101-97-96N/A
9/30/202024-84-73-71N/A
6/30/202039-67-49-46N/A
3/31/202039-66-49-47N/A
12/31/201939-65-50-48N/A
9/30/201923-80-62-60N/A
6/30/20198-94-73-71N/A
3/31/20198-87N/A-64N/A
12/31/20187-80N/A-56N/A
9/30/20187-75N/AN/AN/A
6/30/20187-70N/A-56N/A
3/31/20187-63N/A-53N/A
12/31/20177-56N/A-50N/A
9/30/20177-50N/AN/AN/A
6/30/20178-44N/A-40N/A
3/31/20177-39N/A-34N/A
12/31/20167-34N/A-27N/A
9/30/20166-27N/A-23N/A
6/30/20165-21N/A-18N/A
3/31/20165-19N/A-16N/A
12/31/20154-17N/A-15N/A
9/30/20155-17N/A-17N/A
6/30/20155-17N/A-19N/A
3/31/20156-17N/A-17N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat GNFT.Y de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.4% ).

Winst versus markt: Er wordt verwacht dat GNFT.Y de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat GNFT.Y binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van GNFT.Y ( 11% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van GNFT.Y ( 11% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat GNFT.Y binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/03/11 00:07
Aandelenkoers aan het einde van de dag2026/03/09 00:00
Inkomsten2025/06/30
Jaarlijkse inkomsten2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Genfit S.A. wordt gevolgd door 14 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank